HOME >> MEDICINE >> NEWS
Italian researchers find fenretinide cuts the risk of second breast cancers in young women

A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] a drug related to vitamin A significantly cuts the risk of a second breast cancer among younger patients.

The Italian research team reporting the findings on-line (Thursday 4 May) in Annals of Oncology[2], are sufficiently convinced of the drug's protective potential to call for a trial to test its use as a preventive in pre-menopausal healthy women at high risk of the disease. They are now seeking international partners and funding for such a trial.

The women in the long-term follow-up comprised a sub-group of 1,700 60% of the patients in a 10-centre trial lead by Professor Umberto Veronesi and co-ordinated by Milan's Istituto Nazionale Tumori when he was its director. The study, which began in 1987, randomised more than 2,800 women to receive 200 mg fenretinide daily for five years or no extra treatment after surgery for early-stage breast cancer.

The new analysis, also lead by Professor Veronesi, who is now Director of the European Institute of Oncology in Milan, followed the 1,739 patients who had been recruited by the Istituto Nazionale Tumori centre, investigating whether these patients developed a second cancer either in the treated breast or the other breast.

Co-author Dr Andrea Decensi, Director of the Department of Medical Oncology at the Galliera Hospital in Genoa, said: "We followed these patients for between 12 and 16 years and we found 168 second breast cancers in the fenretinide arm and 190 in the control arm. In post-menopausal women there were actually more cancers in the fenretinide arm than among the controls (85 as against 64). But, among pre-menopausal women there were only 83 second cancers in the fenretinide group compared with 126 in the control group.

Dr Decensi said that overall, this meant a 17% reduction in second cancers among the fenretinide group, which was of borderline statistical significance. But, there we
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-015-367-72181
European Society for Medical Oncology
3-May-2006


Page: 1 2 3

Related medicine news :

1. UCLA, Italian chemists move closer to solving Lou Gehrigs disease mystery
2. Italian doctors get their information on medicines from drug company sales reps
3. Italian public smoking ban leads to fall in hospital heart attack admissions in under 60s
4. UPMC joins Italian government to create $398 million biomedical research center in Sicily
5. Italian law on ART brings problems for doctors and patients
6. Stanford researchers find culprit in aging muscles that heal poorly
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Penn researchers discover novel pathway for increasing good cholesterol
9. Theory of facial aging gets a facelift from UT Southwestern researchers
10. UIC researchers to develop new drugs to fight bioterrorism
11. UQ researchers discover some of the oldest forms of life

Post Your Comments:
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... 26, 2014 Louisiana Back Institute, ... specialists in minimally invasive spine surgery, announces today ... the rapidly growing provider network of orthopedic spine ... coincides with the network’s continuing success providing the ... Louisiana residents who are suffering from orthopedic spine ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... Nov. 24, 2014  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 3, 2014 at The New ... . A live webcast of the Company,s presentation ... feature an overview of the company by Pat Mackin ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
Cached News: